Researchers in Italy conducted a study to evaluate the efficacy of rifaximin therapy on small intestinal bacterial overgrowth (SIBO) in children diagnosed with irritable bowel syndrome (IBS). The study enrolled 50 children with IBS. Each child was tested for SIBO using the lactulose version of the hydrogen breath test. 64% of the children tested positive for SIBO and were treated with rifaximin. One month after the rifaximin therapy the children were evaluated. The rifaximin treatment was deemed to be effective (with no relevant side effects) and the IBS symptoms significantly improved.
Ref: Eur Rev Med Pharmacol Sci 2013 May